๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9115 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:16 UTC
9115
Studies in scope
industry-sponsored, all four open statuses
4955
Recruiting now
open to new participants
2206
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4396 Illinois 2477 Georgia 2346 Arizona 2230
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca104 Eli Lilly and Company87 Merck Sharp & Dohme LLC70 Janssen Research & Development, LLC67 AbbVie66
State
California5299 Florida4396 Illinois2477 Georgia2346 Arizona2230
All 51 states
Target enrolment
to

Trials with a site in Georgia

2346 of 9115 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
NCT06262139MRI Scan
Songqi Gao
Phase 1/2
12
Georgia
2024-07-25
Active, closed
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
NCT06491914Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Regeneron Pharmaceuticals
Phase 3
1,126
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland
2024-07-24
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
Merck Sharp & Dohme LLC
Phase 3
686
Alabama, Alaska, Arizona, California, Florida, Georgia, Louisiana, Nevada
2024-07-24
Active, closed
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
NCT06355531Progressive Supranuclear Palsy
Ferrer Internacional S.A.
Phase 2
241
California, Colorado, Florida, Georgia, Massachusetts, Michigan, New York, North Carolina
2024-07-23
Active, closed
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
NCT06347016Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
311
Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Maryland
2024-07-23
Active, closed
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
446
California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland, Michigan
2024-07-22
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVIยฎ (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752Relapsing Multiple Sclerosis, Multiple Sclerosis
TG Therapeutics, Inc.
Observational
2,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-07-22
Recruiting
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
NCT06517810Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
SeaStar Medical
Observational
50
Alabama, California, Colorado, Georgia, Illinois, Michigan, Ohio, Pennsylvania
2024-07-19
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3
286
California, Colorado, Florida, Georgia, Kansas, Kentucky, Louisiana, Massachusetts
2024-07-19
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
Celldex Therapeutics
Phase 3
976
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-07-19
Active, closed
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
RayzeBio, Inc.
Phase 1/2
16
Arizona, California, Colorado, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-07-19
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883Inflammatory Bowel Diseases, Crohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
California, Colorado, Florida, Georgia, Louisiana, Missouri, Nevada, North Carolina
2024-07-18
Recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580Generalized Myasthenia Gravis
Vor Biopharma
Phase 3
180
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts
2024-07-17
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naรฏve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649Metastatic Colorectal Cancer
Amgen
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Michigan
2024-07-17
Recruiting
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
NCT06481306Anemia, Sickle Cell, Healthy Volunteers
Bristol-Myers Squibb
Phase 1/2
224
Alabama, California, Connecticut, Georgia, Illinois, Kansas, Maryland, Massachusetts
2024-07-17
Active, closed
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
NCT06427395Primary Biliary Cholangitis
Zydus Therapeutics Inc.
Phase 3
102
California, Colorado, Connecticut, Florida, Georgia, Indiana, New York, North Carolina
2024-07-16
Recruiting
Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
NCT05399537Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
Vantive Health LLC
Phase 3
40
Alabama, California, Florida, Georgia, Michigan, Ohio, Pennsylvania, South Carolina
2024-07-12
Recruiting
Galleriยฎ in the Medicare Population.
NCT05673018Cancer
GRAIL, Inc.
Not applicable
50,000
Arkansas, California, Florida, Georgia, Indiana, Louisiana, Missouri, Oregon
2024-07-12
Recruiting
Zopa Retreatment and Vector Shedding in Adults With RRP
NCT06538480Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
Precigen, Inc
Phase 4
30
Georgia, Maryland, Ohio
2024-07-11
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180Advanced Melanoma
Replimune, Inc.
Phase 3
400
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Iowa
2024-07-11
Active, closed
Study to Assess the Efficacy and Safety of Ioveraยฎยฐ System in Subjects With Upper Extremity Spasticity
NCT06340451Spasticity, Cerebral or Spinal Condition
Pacira Pharmaceuticals, Inc
Not applicable
132
California, Florida, Georgia, Kansas, Missouri, New Jersey, New York, Pennsylvania
2024-07-11
Recruiting
Lumasonยฎ Infusion vs. Bolus Administrations
NCT06400004Heart Diseases
Bracco Diagnostics, Inc
Phase 3
106
California, Georgia, Massachusetts, Oregon, Texas
2024-07-10
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC
Phase 3
136
California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa, Maryland
2024-07-09
Active, closed
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
NCT06325566Degenerative Disc Disease
Mesoblast, Ltd.
Phase 3
300
Arizona, California, Colorado, Florida, Georgia, Hawaii, Kansas, Kentucky
2024-07-03
By invitation
Continuation Protocol for Obstructive Sleep Apnea (OSA)
NCT06566820OSA
Apnimed
Phase 3
1,280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-07-03
Active, closed
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
NCT06293365Sjรถgrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Novartis Pharmaceuticals
Phase 2
155
Alabama, California, Florida, Georgia, Indiana, Louisiana, Michigan, Ohio
2024-07-02
Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
Walden Biosciences
Phase 2
96
California, Colorado, Florida, Georgia, Illinois, South Dakota, Texas
2024-07-02
Active, closed
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NCT06455098Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
353
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2024-06-28
Recruiting
Global Paradise System US Post Approval Study
NCT06297291Hypertension, Cardiovascular Diseases, Vascular Diseases
ReCor Medical, Inc.
Observational
1,000
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas, Louisiana
2024-06-28
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
AbbVie
Phase 3
1,400
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-27
Recruiting
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
NCT06207032Cancer
Tempus AI
Observational
500
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-06-26
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178Head and Neck Squamous Cell Carcinoma
Merus B.V.
Phase 3
621
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-06-25
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,530
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-06-24
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Colorado, District of Columbia, Florida, Georgia, New York, Texas, Virginia
2024-06-20
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2024-06-20
Recruiting
The Golazoยฎ Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
NCT06321575Peripheral Arterial Disease
Nipro Vascular Innovations Americas, Inc
Not applicable
159
Arizona, California, Florida, Georgia, Hawaii, Louisiana, Massachusetts, New Jersey
2024-06-20
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
Celgene
Phase 3
850
Alabama, Alaska, Arizona, California, Florida, Georgia, Illinois, Iowa
2024-06-19
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273Large B-cell Lymphoma
Allogene Therapeutics
Phase 2
250
Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida, Georgia
2024-06-18
By invitation
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent ฮฒ-Thalassemia Who Received EDIT-301
NCT06363760Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
Editas Medicine, Inc.
Observational
54
California, Colorado, Connecticut, Florida, Georgia, Minnesota, New York, North Carolina
2024-06-17
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
Boehringer Ingelheim
Phase 3
6,712
Alabama, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-06-17
Active, closed
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
NCT06334133Diabetes Mellitus, Type 1
vTv Therapeutics
Phase 3
150
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Indiana
2024-06-14
Recruiting
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136Atopic Dermatitis
AbbVie
Phase 3
200
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-14
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT06557265Lupus Nephritis, Primary Membranous Nephropathy
Nkarta, Inc.
Phase 1/2
120
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan
2024-06-13
Recruiting
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128Ulcerative Colitis
Takeda
Phase 4
60
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky
2024-06-12
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer
Tubulis GmbH
Phase 1/2
250
Alabama, Connecticut, Georgia, Kentucky, Massachusetts, New Jersey, New York, Ohio
2024-06-12
Recruiting
Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks
NCT06452914Diabetic Neuropathy
Endocrine Research Solutions
Not applicable
80
Georgia
2024-06-11
Recruiting
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964Schizophrenia, Cognitive Impairment
Alto Neuroscience
Phase 2
82
California, Florida, Georgia, Illinois, Maryland, Massachusetts, New York
2024-06-11
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
550
California, Florida, Georgia, Michigan, Missouri, New Jersey, New York, North Dakota
2024-06-11
Recruiting
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
NCT06285643Parkinson Disease
AskBio Inc
Phase 2
127
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-06-11
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682Atopic Dermatitis
LEO Pharma
Phase 3
195
Alabama, Arkansas, California, Florida, Georgia, Michigan, Oklahoma, Oregon
2024-06-10
Recruiting
VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions
NCT06193954Chronic Total Occlusion of Coronary Artery, Chronic Angina
VasoStar, LLC
Not applicable
10
Georgia, Ohio
2024-06-10
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2024-06-10
Active, closed
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167Head and Neck Squamous Cell Carcinoma
Exelixis
Phase 2/3
600
California, Florida, Georgia, Illinois, Iowa, Missouri, New Hampshire, New Jersey
2024-06-07
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
108
Arizona, Colorado, Florida, Georgia, Indiana, Ohio, Texas
2024-06-07
Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297Neutropenia
X4 Pharmaceuticals
Phase 3
176
Arizona, California, Florida, Georgia, Iowa, Massachusetts, Michigan, Missouri
2024-06-06
Active, closed
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249Systemic Lupus Erythematosus
GlaxoSmithKline
Phase 4
303
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan
2024-06-06
Recruiting
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
NCT06270316Fabry Disease
UniQure Biopharma B.V.
Phase 1/2
12
Alabama, Georgia, Illinois, Minnesota, New York, Pennsylvania, Utah, Virginia
2024-06-05
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Amgen
Phase 3
563
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2024-06-05
Active, closed
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
NCT06097832Light Chain (AL) Amyloidosis
Nexcella Inc.
Phase 1/2
45
California, Georgia, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New York
2024-06-05
Recruiting
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
NCT05861986Muscular Atrophy, Spinal
Hoffmann-La Roche
Phase 4
28
Arkansas, Colorado, Florida, Georgia, Illinois, Michigan, New York, Pennsylvania
2024-05-30
Recruiting
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
NCT06366789AML With Gene Mutations
Lomond Therapeutics Holdings, Inc.
Phase 1
150
California, Georgia, Illinois, Kansas, Maryland, New York, North Carolina, Ohio
2024-05-29
Active, closed
A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM
NCT06167655Headache Migraine Chronic
ShiraTronics
Not applicable
250
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-05-29
Recruiting
Post-Market Clinical Study of Functional Motion Outcomes in Subjects Treated With the Minuteman Device
NCT06355791Degenerative Conditions of the Lumbar Spine, Lumbar Spinal Stenosis, Spondylolisthesis
Spinal Simplicity LLC
Not applicable
150
Georgia, Indiana, Kansas, Minnesota, Oregon, West Virginia
2024-05-29
Recruiting
CraniSeal Post Approval Study
NCT06406790Leak, Cerebrospinal Fluid
Pramand LLC
Phase 4
224
California, Florida, Georgia, Massachusetts, Minnesota, New York, South Carolina
2024-05-29
Recruiting
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464Prader-Willi Syndrome
Harmony Biosciences Management, Inc.
Phase 3
134
California, Colorado, Delaware, Georgia, Illinois, Indiana, Maryland, Minnesota
2024-05-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.
Phase 3
762
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-05-24
Active, closed
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
NCT06347133Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
1,456
Alabama, California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas
2024-05-21
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
550
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2024-05-21
Active, closed
A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571Acute Myeloid Leukemias
Syndax Pharmaceuticals
Phase 1
96
Arizona, California, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2024-05-21
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 1
575
Arizona, California, Georgia, Michigan, New York, Ohio, Texas, Utah
2024-05-20
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665Asthma
AstraZeneca
Phase 3
440
Alaska, Arizona, Arkansas, California, Colorado, Delaware, Florida, Georgia
2024-05-20
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2024-05-20
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2024-05-20
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
AbbVie
Phase 3
421
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana
2024-05-19
Active, closed
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
NCT06369467Food Allergy
Regeneron Pharmaceuticals
Phase 1
6
Florida, Georgia, Massachusetts, New York, Pennsylvania
2024-05-17
Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT06414954Myasthenia Gravis, Myasthenia Gravis, MuSK
NMD Pharma A/S
Phase 2
84
California, Colorado, Florida, Georgia, Missouri, North Carolina, Ohio, Oregon
2024-05-16
Recruiting
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
NCT06055439Neuroendocrine Tumors, Colorectal Cancer, Gastric Cancer
Chimeric Therapeutics
Phase 1/2
135
Georgia, Illinois, Pennsylvania, Tennessee
2024-05-15
Recruiting
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRTยฎ) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
NCT06635954Cancer, Immunotherapy, PD-1, PD-L1
Oxford Biodynamics Inc.
Observational
2,000
Connecticut, Georgia, South Carolina
2024-05-14
Recruiting
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964Bipolar Depression
Intra-Cellular Therapies, Inc.
Phase 3
384
Alabama, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-05-14
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
Biohaven Therapeutics Ltd.
Phase 2/3
390
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Kentucky, Louisiana
2024-05-13
Active, closed
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZOยฎ for 12 Months
NCT06385509Hypogonadism
Tolmar Inc.
Phase 4
110
Arizona, California, Florida, Georgia, Maryland, Nebraska, New York, North Carolina
2024-05-10
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
Sanofi
Phase 3
1,541
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2024-05-08
Recruiting
Endovascular AAA Intervention Using the GOREยฎ EXCLUDERยฎ Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
NCT06218875AAA - Abdominal Aortic Aneurysm
W.L.Gore & Associates
Observational
2,000
Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana
2024-05-07
Recruiting
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
NCT06138639Duchenne Muscular Dystrophy
Solid Biosciences Inc.
Phase 1/2
60
Arkansas, California, Georgia, Illinois, Missouri, Ohio, Oregon, Pennsylvania
2024-05-06
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
Merck Sharp & Dohme LLC
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, North Dakota
2024-05-03
Active, closed
PoNSยฎ Therapy for Gait and Balance Deficits in Chronic Stroke Survivors: A Single-Arm Study
NCT06336720Chronic Stroke Survivors
Helius Medical Inc
Not applicable
30
Florida, Georgia, Massachusetts, New York
2024-05-01
By invitation
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants โ‰ฅ5 to โ‰ค65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
NCT06431893Homocystinuria
Travere Therapeutics, Inc.
Phase 3
100
Arizona, Connecticut, Georgia, Illinois, Maine, Maryland, New York, North Carolina
2024-04-30
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Eli Lilly and Company
Phase 3
10,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-04-30
Active, closed
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
NCT06294236Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Sana Biotechnology
Phase 1
7
Colorado, Georgia, Maryland, Massachusetts, Washington
2024-04-29
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
Apogee Therapeutics, Inc.
Phase 2
470
California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2024-04-29
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961End Stage Kidney Disease
CSL Behring
Phase 2/3
3,110
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-04-27
Recruiting
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
NCT06413433Binge-Eating Disorder
Axsome Therapeutics, Inc.
Phase 3
450
California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2024-04-26
Recruiting
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
NCT06345339Hypothyroidism
AbbVie
Phase 2/3
2,800
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2024-04-26
Recruiting
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
NCT06384807Solid Tumor
Biohaven Therapeutics Ltd.
Phase 1/2
500
California, District of Columbia, Florida, Georgia, Michigan, Missouri, New York, Oklahoma
2024-04-22
Active, closed
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551Osteogenesis Imperfecta
Amgen
Phase 3
111
Alabama, Arizona, California, Delaware, Florida, Georgia, Indiana, Maryland
2024-04-22
Active, closed
Blood Purification for the Treatment of Pathogen Associated Shock
NCT05011656Septic Shock
ExThera Medical Corporation
Not applicable
15
District of Columbia, Georgia, Michigan, Minnesota, Oregon, Pennsylvania, Texas
2024-04-19
Recruiting
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754Crohn's Disease
Takeda
Phase 4
50
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2024-04-18
Active, closed
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06253221Cardiomyopathy, Hypertrophic
Bristol-Myers Squibb
Phase 3
44
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-04-17
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
argenx
Phase 3
119
Arizona, California, Florida, Georgia, Kansas, New Jersey, North Carolina, Ohio
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-04-16
Rows per page Showing 1101–1200 of 2346
Previous 10 11 12 13 14 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia?page=12

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,115 studies in total at the last sync on 24 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,346 of those studies with a site in Georgia.

How many clinical trials are recruiting in Georgia?

1,211 of the 2,346 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:16 UTC sync. A further 40 have not yet opened recruitment, 1,035 are active but closed to new participants, and 60 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.